Thursday, 2 March 2023, 09:45 HKT/SGT

Source: Eisai

TOKYO, Mar 2, 2023 - (JCN Newswire) - Biogen Japan Ltd. and Eisai Co., Ltd. announced today the termination of the co-promotion agreement that has been in place since January 2018 for Biogen Japan's multiple sclerosis (MS) treatments TECFIDERA (dimethyl fumarate), TYSABRI (natalizumab, genetic recombinant) and AVONEX (interferon beta 1a, genetic recombinant) in Japan as of March 31, 2023.

The two companies have been jointly engaged in promotional activities for MS treatments in Japan. However, since a certain objective has been achieved regarding penetration of the products into the Japanese market, the two companies decided to terminate this co-promotion agreement. As a result, Biogen Japan will have full responsibility for all operations related to the products after a transition period between the two companies. Upon termination of this agreement, Biogen will pay Eisai 31 million USD.

The termination of this co-promotion agreement does not impact any of the other agreements between Biogen and Eisai.

For more information, visit www.eisai.com/news/2023/news202315.html.

Contacts:

Biogen Japan Ltd.
MEDIA CONTACT:
Public Relations & CSR Department
MOB: +81-(0)70-1501-4315
TEL: +81-(0)3-3275-1745

Eisai Co., Ltd.
MEDIA CONTACT:
Public Relations Department
TEL: +81-(0)3-3817-5120

Topic: Press release summary
Source: Eisai
Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network

Eisai

Dec 11, 2025 18:41 HKT/SGT

Eisai Rated "A", the Highest Rating by CDP in Both Climate Change and Water Security Categories for the Second Consecutive Year

Dec 9, 2025 17:51 HKT/SGT

"LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Included in China's Commercial Insurance Innovative Drug List

Dec 4, 2025 17:36 HKT/SGT

Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI(R) (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at CTAD 2025

Dec 3, 2025 17:19 HKT/SGT

New Data Presented at CTAD 2025 Confirms Pharmacological Effect of LEQEMBI(R) (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF

Dec 2, 2025 23:01 HKT/SGT

Eisai Presents New Data on Anti-Tau Antibody Etalanetug (E2814) at CTAD 2025

Nov 28, 2025 22:00 HKT/SGT

Eisai Submits New Drug Application for Subcutaneous Formulation of "LEQEMBI(R)" for the Treatment of Early Alzheimer's Disease in Japan

Nov 26, 2025 18:42 HKT/SGT

Eisai Completes Rolling Submission to US FDA for LEQEMBI(R) IQLIK(TM) (lecanemabirmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status

Nov 17, 2025 21:08 HKT/SGT

"LEQEMBI(R)" (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in the United Kingdom

Oct 30, 2025 13:43 HKT/SGT

Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP012 Trial in Unresectable, Non-Metastatic Hepatocellular Carcinoma

Oct 28, 2025 23:30 HKT/SGT

Merck & Co., Inc. and Eisai Announce WELIREG(R) (belzutifan) Plus LENVIMA(R) (lenvatinib) Met Primary Endpoint of Progression-Free Survival (PFS) in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma

More news >>

News Alerts


Home \| About us \| Services \| Partners \| Events \| Login \| Contact us \| Privacy Policy \| Terms of Use \| RSS

US: +1 214 890 4418 \| China: +86 181 2376 3721 \| Hong Kong: +852 8192 4922 \| Singapore: +65 6549 7068 \| Tokyo: +81 3 6859 8575

Connect With us: